Prevalence of Epstein–Barr virus infection and characteristics of lymphocyte subsets in newly onset juvenile dermatomyositis

Background The underlying etiology of juvenile dermatomyositis (JDM) is unknown. T cell deficiency as well as Epstein–Barr virus (EBV) infection had been suspected to be involved in the pathogenesis, but it has been poorly evaluated in JDM patients. Methods This study described the traits of T and B...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of pediatrics : WJP Vol. 17; no. 2; pp. 205 - 209
Main Authors Zheng, Qi, Zhu, Kun, Gao, Cai-Na, Xu, Yi-Ping, Lu, Mei-Ping
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.04.2021
Department of Rheumatology,Immunology and Allergy,Children's Hospital,Zhejiang University School of Medicine,57#Zhu Gan Road,Hangzhou 310000,China%Department of Pathology,Children's Hospital,Zhejiang University School of Medicine,Hangzhou,China
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background The underlying etiology of juvenile dermatomyositis (JDM) is unknown. T cell deficiency as well as Epstein–Barr virus (EBV) infection had been suspected to be involved in the pathogenesis, but it has been poorly evaluated in JDM patients. Methods This study described the traits of T and B lymphocyte subsets in newly onset JDM patients and the incidence of EBV infection in JDM patients compared with match controls. Newly developed JDM patients from 2014 to 2018 were included in the study. Lymphocytes with different markers (CD3 + , CD3 + CD4 + , CD3 + CD8 + , CD3 − CD19 + and CD3 − CD16 + CD56 + ) were tested with flow cytometry in the first admission or after 6 months of treatment. Statistical analysis was conducted to compare the EBV infection in the group of JDM patients and controls. Results We observed that JDM patients had higher positive rate of Epstein–Barr nuclear antigen-immunoglobulin G (IgG) ( P  < 0.0001) as well as EBV capsid antigen-IgG ( P  < 0.05) than normal controls. CD3 − CD16 + CD56 + lymphocyte was found to be extremely low in early stage of JDM patients, but increased after 6 months of treatment ( P  = 0.0091). Conclusions The level of CD3 − CD16 + CD56 + cells may associate with the clinical course of JDM. EBV may act as an environmental factor predisposing patients to the development of JDM.
ISSN:1708-8569
1867-0687
DOI:10.1007/s12519-019-00314-7